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Abstract 
 
Background: The COVID-19 pandemic has already claimed considerable lives. There are major 
concerns in Africa due to existing high prevalence rates for both infectious and non-infectious 
diseases and limited resources in terms of personnel, beds and equipment. Alongside this, concerns 
that lockdown and other measures will have on prevention and management of other infectious 
diseases and non-communicable diseases (NCDs). NCDs are an increasing issue with rising 
morbidity and mortality rates. The World Health Organization (WHO) warns that a lack of nets and 
treatment could result in up to 18 million additional cases of malaria and up to 30,000 additional 
deaths in sub-Saharan Africa. Objective: Document current prevalence and mortality rates from 
COVID-19 alongside economic and other measures to reduce its spread and impact across Africa. In 
addition, suggest ways forward among all key stakeholder groups.  Our Approach: Contextualise the 
findings from a wide range of publications including internet-based publications coupled with input 
from senior-level personnel. Ongoing activities: Prevalence and mortality rates are currently lower in 
Africa than among several Western countries and the USA. This could be due to a number of factors 
including early instigation of lockdown and border closures, the younger age of the population, lack of 
robust reporting systems and as yet unidentified genetic and other factors. Innovation is accelerating 
to address concerns with available equipment. There are ongoing steps to address the level of 
misinformation and its consequences including fines. There are also ongoing initiatives across Africa 
to start addressing the unintended consequences of COVID-19 activities including lockdown 
measures and their impact on NCDs including the likely rise in mental health disorders, exacerbated 
by increasing stigma. Strategies include extending prescription lengths, use of drones, telemedicine 
and encouraging vaccination. However, these need to be accelerated to prevent increased morbidity 
and mortality Conclusion: There are multiple activities across Africa to reduce the spread of COVID-
19 and address misinformation, which can be catastrophic, assisted by the WHO and others, which 
appear to be working in a number of countries. Research is ongoing to clarify the unintended 
consequences given ongoing concerns to guide future activities. Countries are learning from each 
other.   
 
1. Introduction 
 
1.1 COVID-19 and key risk factors 
The novel coronavirus named SARS-CoV-2 causing COVID-19 was first reported in Hubei Province in 
China in December 2019 (1-4), and has subsequently spread to all continents (5). COVID-19 is 
transmitted from person to person through respiratory droplets as well as directly through touching 
surfaces and other fomites (6-10). Initial observations from China suggested a case fatality ratio 
(CFR) of 2.3% (3). In their  July 1 2020 report, the World Health Organization (WHO) suggested a 
case fatality ratio (CFR) of 4.91% based on 10,357,662 confirmed cases worldwide and 508,055 
recorded deaths (5). 
 
Increased morbidity and case fatality from COVID-19 is associated with a number of underlying health 
conditions, alongside male gender and older age. These include hypertension, cardiovascular disease 
(CVD), diabetes, obesity, chronic kidney disease, chronic obstructive pulmonary disease (COPD), 
history of smoking and shortness of breath, as well as some immunosuppressive conditions and 
potentially blood type (11-33). Ethnicity, particularly for people of Black Afro-Caribbean origin 
alongside those from South Asia, has also emerged as a significant factor associated with a higher 
mortality risk versus the white population in Europe and the United States of America (USA) (11, 25, 
34-37). However, it is currently not fully understood how ethnicity, poverty and deprivation, cultural 
and behavioural differences, as well as underlying health, interplay in morbidity or mortality risk 
especially with currently lower mortality rates in Africa at the end of June 2020 compared with a 
number of European countries and the USA (5).  
 
1.2 Prevention and treatment of COVID-19 
Response activities to the COVID-19 pandemic typically included personal protection through physical 
distancing and hand washing coupled with respiratory precautions through face covering (6, 38-41). 
Increased testing and screening with contact tracing are fundamental to transmission control, and this 
has been variably combined with “locking down” of public places including educational 
establishments, retail outlets, factories and offices combined with closure of borders and quarantining 
suspected persons (41-43). Case management of patients includes supportive care with 
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supplementary oxygen coupled with ventilatory support for those most severely affected  (6, 12, 44-
47). Depending on the threshold for hospital admission, it is estimated that up to 17% of hospitalized 
patients will require intensive care, with an appreciable proportion needing mechanical ventilation (26, 
48-50). This is a concern even in high-income countries where there have been challenges with the 
availability of critical care beds, appropriately trained staff and personal protective equipment (PPE) 
(15, 51-55).  
 
An encouraging example of a positive response among low- and middle- income countries (LMICs) is 
Vietnam where multiple activities including extensive testing, contact tracing, and social distancing, 
under the government slogan “Fighting the epidemic is like fighting against the enemy”, have been 
successful in limiting the tranmission of COVID-19 with only 355 confirmed cases by the end of June 
2020 and no recorded attributable mortality (5, 56-60). 
 
Currently, there does not appear to be a cure for COVID-19; however, there are a number of 
medicines undergoing trials including antivirals, steroids, antimalarials, immunomodulators, and 
herbal medicines, some of which have shown positive findings although there have been concerns 
with the trial design of a number of studies (61-70).  
 
The most promising therapeutic breakthrough to date has come from the UK-based adaptive 
randomised Recovery trial (62, 70, 71). The low cost corticosteroid dexamethasone has recently been 
shown to significantly reduce mortality in the most severely affected patients with COVID-19; patients 
with an oxygen requirement and those requiring ventilatory support (70, 71). The prescribing of 6mg 
of dexamethasone daily for 10 days is now recommended for widespread use in the UK unless 
contraindicated for other reasons as well as endorsed by the National Institute of Health (NIH) in the 
USA (72, 73). However, currently optimal dosing and duration of dexamethasone in COVID-19 is 
unknown; consequently, current recommendations reflect those used in the Recovery trial. 
 
Initial studies with remdesivir failed to demonstrate clinical benefit over placebo although these were 
underpowered (74-76). More recently, larger scale studies conducted by NIH in the USA have shown 
encouraging results including a reduction in the time to recovery and a trend towards lower mortality 
(hazard ratio for death = 0.70) leading to the issuance of an Emergency Use Authorization by the US 
FDA as well as endorsement by the European Medicines Agency and the NHS in the UK (77-81). 
However, further studies are needed before the prescribing of remdesivir can be fully endorsed. 
 
However, much controversy surrounds the use of chloroquine and hydroxychloroquine with or without 
azithromycin for both the prevention and treatment of COVID-19. Following  initial studies in China, 
coupled with the findings of Gautret et al. (2020) (66, 82-85), its use was endorsed among a number 
of governments and medical societies (86-91). However, the lack of a comparator arm in the initial 
studies has been heavily criticised coupled with concerns with side-effects including cardiac side-
effects with hydroxychloroquine (84, 92-96) as well as reports of fatal overdoses  (97-100). Recent 
studies have failed to demonstrate any clinical benefit for both the prevention and treatment of 
COVID-19 (69, 85, 101, 102). The study by Mehra et al. (2020) also showed increased mortality with 
chloroquine or hydroxychloroquine; however, this has now been retracted subject to external auditing 
(103, 104). The European Medicines Agency now advises caution with the prescribing of 
hydroxychloroquine outside of clinical trials (105), and the WHO has halted the hydroxychloroquine 
arm in its ongoing Solidarity Trial with the NIH in the USA also halting the use of hydroxychloroquine 
in its studies (62, 106, 107). In South Africa, the South African Pharmacy Council has also warned 
against the misuse of hydroxychloroquine for the treatment of COVID-19, which builds on concerns 
from the regulatory agency given the lack of evidence (108, 109). 
 
The antiretroviral treatment (ART) lopinavir-ritonavir, which showed activity against MERS-CoV, has 
been recommended for treating COVID-19 patients alongside arbidol (68, 110-113). However, there 
have also been contrasting data regarding its effectiveness in COVID-19 patients, with most studies 
failing to show any clinical benefit including the UK Recovery study (62, 110, 114, 115). 
Consequently, lopinavir-ritonavir cannot currently be recommended for use outside of clinical trials. A 
recent study though by Hung et al. (2020) found that early triple antiviral therapy with interferon beta-
1b, lopinavir/ritonavir and ribavirin alleviated the symptoms and shortened the duration of viral 
shedding and hospital stay compared with lopinavir/ ritonavir alone in patients with mild to moderate 
COVID-19 (116). Any positive findings though with combination therapies need confirmation before 
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they can be endorsed. Studies regarding the potential effectiveness of nasal irrigation are also 
ongoing (117, 118). This follows a pilot randomised study showing improvements in the duration of 
symptoms and viral shedding in patients with upper respiratory tract infections (119), with a post-hoc 
re-analysis with a focus on those infected with coronaviruses also showing benefit (120).  
  
A number of other treatments focusing on the late inflammatory complications of COVID-19 (121-123) 
are also under review. These include tocilizumab, which is widely used in rheumatoid arthritis and 
blocks Interleukin-6 (IL-6), a combination of emapalumab, anakinra and sarilumab (15, 124-129), and 
interferons (130-133). These are currently not recommended for use outside of clinical trials. Ongoing 
studies are also using the plasma from affected patients along with prior titration of neutralising 
antibodies (62, 132, 134-136), and anticoagulants for hypercoagulability states (126, 137-140). Again, 
these experimental therapies cannot be recommended until more clinical trial data becomes available.  
 
There has also been controversy surrounding BCG vaccination as possible protection against COVID-
19 (141, 142). The WHO is warning against claims of effectiveness based on current ecological 
studies, with the South African Government and leading scientists also warning against diverting 
stocks away from neonatal vaccination programmes given concerns with shortages until more trial 
data becomes available (142-145).  
 
There are also concerns with the inappropriate use of medicinal plants to prevent and treat COVID-
19, which such use particularly prevalent in some sub-Saharan African countries as this can cause 
more harm than good (146-150). Safety fears are enhanced by the lack of data when used to prevent 
or treat COVID-19 along with other treatments that patients may be taking including antivirals, 
antibiotics as well as medicines for non-communicable diseases (NCDs) (146, 150). We are aware 
that some herbal medicines are showing promise based on in-vitro and small-scale clinical studies 
(64, 150-154). However, their use outside of such studies is a concern until more data becomes 
available especially if their use causes delay in patients seeking appropriate care from healthcare 
professionals as their symptoms develop (150). 
 
The controversies and issues surrounding a number of the treatments, the redaction of recent studies, 
as well as concerns with trial design in a number of studies (62, 67, 92, 93, 104, 155), means it is 
essential that treatment recommendations should only be made once the results of robust trials are 
known (156). 
 
1.3 Consequences of lockdown and other measures to prevent and treat COVID-19 
There are a number of unintended consequences arising from COVID-19. These include 
Governments diverting personnel and resources away from priority diseases including both infectious 
and non-infectious diseases. Reducing antimicrobial resistance (AMR) is a key activity across 
countries especially among LMICs as it increases morbidity, mortality and costs (157-160). However, 
diverting attention away from AMR, including ongoing efforts to reduce inappropriate self-purchasing 
of antibiotics, which is prevalent across many countries, as well as routine immunisation programmes 
for existing infectious diseases, will inevitably have a significant impact on future patient care (161-
173). Self-purchasing of antibiotics is a particular concern with the clinical presentation of COVID-19 
overlapping with other infectious diseases including tuberculosis (TB), viral and bacterial respiratory 
tract infections, and pneumonia, making a differential diagnosis challenging exacerbated by limited 
diagnostic facilities in most communities (168, 174, 175). In hospitals, establishing antimicrobial 
stewardship programmes and other activities (168, 176-181) can improve antibiotic prescribing where 
there is little evidence of bacterial co-infection (168, 182, 183). Consequently, it is essential that such 
activities be introduced where necessary to guide future antibiotic prescribing among suspected 
COVID-19 patients (183). 
 
We are aware that the Ebola outbreak in Guinea, Liberia, and Sierra Leone between 2014 and 2016 
resulted in as many people dying from HIV/AIDS, TB, and malaria as Ebola due to reduced access to 
health care (161, 184, 185). There are also concerns that an appreciable reduction in the distribution 
of protective bed nets (75%) and medicines for treating malaria due to lockdown measures, combined 
with no media campaigns, could result in up to 18 million additional cases and up to 30,000 additional 
deaths in sub-Saharan Africa alone compared to 2018 (162, 184, 186). Whilst the latest evidence 
suggests that HIV positive patients do not have a higher COVID-19 infection rate, or a significantly 
different disease course than HIV-negative individuals (187-190), patients’ fears of contracting 
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COVID-19 when they attend clinics, as well as limited access to health facilities and treatment during 
lockdown, will negatively impact on treatment and adherence to medicines as well as initial diagnosis 
(164, 184, 189, 191-193). Medicine supplies can potentially be addressed through differentiated 
service delivery and other programmes (164, 189, 194). Telemedicine and other technologies could 
also potentially help with consultations, with mobile technologies helping with tracking and tracing 
COVID-19 patients (195-197).  
 
There are also concerns that lockdown measures will negatively impact of the management of 
patients with non-communicable diseases (NCDs) (31). This includes a lack of support and access to 
facilities to improve lifestyle management, monitor patient and regularly provide essential medicines 
(31). Ongoing national plans to reduce morbidity and mortality due to NCDs, especially CVD and 
diabetes, across continents including Africa (198-201) could also be compromised by reduced access 
to medicines, cancelled or missed appointments due to patients’ reduced access and fear of coming 
into contact with COVID-19 patients in healthcare facilities, and not following lifestyle advice (31, 202, 
203). However, we are aware that governments are committing extra resources to try and minimise 
these unintended consequences (204). Issues relating to medical supplies can again be addressed by 
measures to extend prescription lengths (205, 206) as well as home delivery of medicines, with 
concerns with consultations potentially addressed through technologies such as telemedicine (196, 
207, 208). 
 
Other serious consequences include the exacerbation of mental health conditions during lockdown, 
the implications for frontline healthcare workers in terms of their health and wellbeing, and anxiety of 
citizens about their health (209-222). Patients with COVID-19 are also at increased risk of requiring 
psychotropic medicines because mild-to-moderate illness may result in adverse psychological effects 
from the diagnosis, from the symptoms, the need for forced isolation, any associated loss of income, 
and the potential risk of death. This might trigger new psychiatric symptoms or exacerbate underlying 
psychiatric conditions. In moderate-to-severe clinical situations, there is a risk that patients could 
develop altered states of consciousness such as hypo- or hyperkinetic delirium, which may require 
treatment with psychotropic medications (223). In addition, some of the medical treatments that have 
been proposed for COVID-19 could contribute to onset or worsening of psychiatric symptoms. These 
include psychiatric disturbances with antivirals and steroids as well as depressive-dysphoric 
experiences with interferons (224-227). 
 
In addition, patients with existing mental illnesses may well have difficulties with accessing regular 
help during the pandemic unless pro-actively addressed (228, 229). This includes continued access to 
medicines and treatments for those with long-term mental health conditions since sudden 
discontinuation should be avoided (215). Worsening of mental health may be greater in patients with 
conditions such as schizophrenia with challenges in continuing active case management in the 
community during the pandemic as well as concerns with administering long-acting injections where 
pertinent, and performing regular blood tests in patients prescribed clozapine (230). Pro-active and 
timely support is needed for all patients with mental health conditions to avoid deteriorating conditions 
(214-216, 231). There are also reports of an increase in gender-based violence across countries, 
including African countries, as a result of lockdown measures, which also needs addressing going 
forward (232-236). 
 
1.4 Specific challenges of COVID-19 in Africa 
COVID-19 poses a particular challenge for the African continent because of existing high prevalence 
rates of other infectious diseases including  human immunodeficiency virus (HIV)/ acquired 
immunodeficiency syndrome (AIDS), TB, cholera, and malaria, along with high rates of AMR and a 
disproportionate burden of poverty (168, 237-243), with ongoing infectious disease initiatives 
appreciably challenged by COVID-19 (168, 176, 178, 244). The presence of multi-morbidity with 
NCDs will aggravate the situation further (245-250), with already high rates of CVD and diabetes a 
growing concern across Africa (198-200). 
 
Alongside this, there are ongoing challenges with available financial and human resources across 
Africa (251-254) including more limited availability of healthcare personnel and hospital beds including 
intensive care unit (ICU) beds (198, 199, 233, 255-259). Reports suggest there were just 1.8 hospital 
beds per 1000 people across Africa before the pandemic, less than a third of those in France (260). 
Oxygen is also not widely available and single room isolation can be a rarity making nosocomial 
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transmission a concern. Overall, there appeared to be less than one ventilator and less than one ICU 
bed per 100,000 people in Africa compared with up to thirty times that number in the USA before the 
pandemic (261), although there is regional variation (253, 256, 259, 262). The availability of 
PPE across Africa was also a challenge in the early stages of the pandemic putting healthcare 
professionals at risk (263-266). However, this is changing with increased local production of PPE, 
new local designs for face masks and ventilators (267-270), as well as improved procurement 
processes enhanced by the recent launch of the pan-African medical supplies platform (271). 
 
Most challenging though is over crowding and lack of running water (and therefore a lack of hand 
washing) among the population, with an estimated 34% to 36% of people in Africa having no access 
to basic household washing facilities and 30% having only limited access (243, 256, 260). This is a 
particular concern among refugees, who require additional efforts to help prevent the spread of the 
virus including education on the rationale behind lockdown activities where pertinent (272, 273).    
 
Given these multiple issues and concerns, the UN Economic Commission for Africa (UNECA) initially 
estimated that the COVID-19 pandemic could potentially lead to 300,000 deaths across Africa and 
push 29 million people into extreme poverty (260). In mid-April, the WHO warned that there could be 
up to 10 million cases of COVID-19 in Africa within six months (274), rising to between 29 million and 
44 million in the first year, with up to 190,000 deaths if containment measures failed (275). By the end 
of June 2020, there were over 303,000 COVID-19 cases among the WHO African countries with over 
6000 deaths giving a CFR of 2.02% (276). Consequently, absolute numbers of COVID-19 related 
deaths to date are still lower in Africa compared with other continents including the Americas and 
Europe (5); however, this is changing as prevalence rates rise. There are also concerns with the 
reliability of the data among some of the African countries due to limited detection capacity and 
reliable tests as well as under-reporting of both deaths and prevalence rates (8, 233, 253, 277-282). 
For instance, there has been no official data released from Tanzania since 8 May with the President 
stating the pandemic has largely been defeated despite concerns with truck drivers testing positive at 
borders and continued ongoing concerns with under-reporting (280, 282, 283). Having said this, there 
have been concerns with the reliability of testing equipment (284). 
 
Other potential factors for currently lower prevalence rates and deaths in Africa compared with other 
continents could be a comparatively younger population as well as rapid instigation of lockdown and 
other measures. which build on experiences with other infectious diseases aided by the African 
Union, WHO Africa and the African Centre for Disease Control (CDC), as well as sensitivity of the 
virus to ambient temperatures (186, 281, 285-289). The African CDC has been actively coordinating a 
strong multilateral response amongst African governments and other stakeholders towards COVID-19 
building on the activities by the WHO in Africa and others (288, 290, 291). The establishment of 
National Public Health Institutes among many African countries has also improved the response to 
public health threats (292). Activities across Africa include developing laboratory expertise, training a 
volunteer health workforce, and risk communication. As mentioned, these built on Africa´s experience 
in dealing with other infectious diseases including Ebola, HIV, malaria and TB (256, 293, 294). The 
United Nations has also established a knowledge hub for COVID-19 to help African countries learn 
from each other (295, 296). Testing has also appreciably increased in recent weeks across Africa 
(297) helped by Africa CDC and the WHO Africa, who have provided testing kits and training, with 48 
African countries able to test for COVID-19 by 29 April 2020 compared with just two countries at the 
start of the pandemic (242, 298, 299).  
 
Most African countries also rapidly instigated lockdown measures as well as social distancing to 
reduce the spread of the virus (233, 243, 260, 300, 301). Similar to several African countries, Ghana 
early on began testing travellers on arrival in the country and isolating positive cases, as well as 
instigating testing among its citizens. Overall, Ghana has one of the highest testing rates in Africa 
having performed between 110,000 and 120,000 tests by the end of April 2020 (302). The 
Government of Ghana also established five key objectives to reduce the spread of the virus (303, 
304). Similar to most African countries, South Africa declared a national state of disaster in terms of 
section 27(2) of the Disaster Management Act, 2002, and implemented a phased approach to 
lockdown with stage 5 introduced on March 27 2020, easing to stage 4 with effect from May 1 2020, 
which remains in place (305, 306). Lockdown measures have now been eased among several 
countries following concerns about the economic and other issues including the potential for 
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increased violence, whilst still maintaining an active response should the need arise (253, 307, 308). 
However, this situation is being actively monitored in case of a spike in prevalence rates.  
 
Medicine shortages are a particular issue in Africa where typically up to 94% of its medicines are 
imported (260, 309, 310), and supply issues can be exacerbated in countries with ongoing conflicts 
(311). However, African countries are already taking steps to address concerns with shortages before 
and during the pandemic including suggesting potential alternatives (312-316). There are also 
ongoing programmes to address the quality of medicines across Africa. The potential for substandard 
and falsified medications is exacerbated when prices appreciably increase and shortages occur 
following endorsement of potential treatments for COVID-19 in the media (97, 317-320). Government 
activities are likely to accelerate with the launch of the Lomé initiative placing falsified and 
substandard medicines on the highest political agenda with ongoing measures to strengthen the legal 
response to these medicines (321).  
 
COVID-19 has accelerated discussions on local pharmaceutical production in Africa (322) with, for 
instance, the East African Community States seeking to support local production of essential medical 
products and supplies. Products include masks, sanitizers and ventilators, to address shortages in the 
region (323). In addition, several local companies have come forward to produce medical equipment 
and other products to manage the pandemic, and this will continue (324-326). This is in line with the 
philosophy to develop regional hubs involving several African countries to address issues of 
economies of scale (327).   
 
1.5 Rationale behind the paper and the objective 
Given the multiple issues and challenges facing African countries, we believe there is an urgent need 
to consolidate ongoing activities across Africa to address the COVID-19 pandemic and to understand 
its impact. Similarly, there is a need to evaluate the impact of re-directing activities away from the care 
of patients in other priority disease areas in Africa towards COVID-19 activities given the likely 
consequences on increased morbidity and mortality alongside the economic and social impact (163, 
186, 285).  
 
We are aware that several regional financial institutions, including the African Development Bank and 
the African Export-Import Bank, have announced significant financial support for this purpose (328, 
329). The commitments of the World Bank and the International Monetary Fund also provide 
additional mechanisms, including suspending debts, to free resources towards the COVID-19 
response (237). These measures should help address existing concerns regarding the financial 
impact of government measures including lockdown measures on the livelihoods of African citizens, 
with many currently working in the informal sector (186, 237, 330).  
 
Containing the spread and impact of COVID-19, including the substantial economic impact, will 
though require a multipronged approach and co-operation among all key stakeholder groups going 
forward, including patients, with countries learning from each other (237). Ongoing activities include 
addressing the considerable misinformation about COVID-19 and potential treatments including 
vaccines and herbal medicines (146, 150, 331-341). The current controversies surrounding 
chloroquine/ hydroxychloroquine is just one example. As a result, there is a recognized need for 
scientific integrity and credibility when developing and discussing possible treatments for COVID-19 in 
line with recommendations from the Council for International Organisations of Medical Sciences 
(156). This is to ensure future public and physician trust in treatment recommendations, which forms 
an integral part of effectively dealing with COVID-19 (97, 342-346). 
 
We are aware that early in the pandemic, Africa CDC, as well as WHO Africa and their partners, 
spearheaded efforts to train and sensitize African governments on the need to effectively counter and 
reduce the levels of misinformation (347-349). Their activities included training on risk communication 
and regular briefings to heads of state as well as relevant sectors of government. Additional efforts 
have also been provided by groups such as the International Alliance of Patients’ Organizations 
(IAPO), which have developed resource hubs to provide reliable and updated information to mitigate 
against misinformation and promote preventative activities (350).  
 
Education among patients can also help reduce any stigma associated with COVID-19 for recovering 
patients and their families as well as any mistrust by the people in their governments (222, 233, 351-
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354). We know that countries and governments have the potential to learn from the evidence base of 
HIV-related stigma interventions to help address such issues, as well as previous pandemics as seen 
with Vietnam (5, 233, 355). Potential activities among patients and their organisations include active 
discussions around how stigma affects different communities, reflections on personal biases, and the 
instigation of institutional support programmes (355, 356). This is important as the COVID-19 
pandemic has already provoked stigmatisation and discriminatory behaviours against people of 
certain ethnic backgrounds as well as anyone perceived to have been in contact with or recovered 
from the virus (351, 354, 357). Having said this, we have seen reasonable knowledge, attitudes and 
practices towards most aspects of COVID-19 among the public in China, Nepal, Pakistan and 
Paraguay although still room for improvement (358-361). Surveys in the UK and US have also shown 
that participants generally had good knowledge about the main means of transmission and the 
common symptoms of COVID-19 (362). In Cameroon, the population is also aware of the disease and 
preventive measures (363). Further research is ongoing regarding why some people fail to adhere to 
suggested preventative measures, and we will be monitoring this (364).  
 
Consequently, the objective of this paper is to summarise and consolidate our knowledge of current 
activities across Africa related to COVID-19 to help provide future guidance to all key stakeholder 
groups. This includes following up on clinical trial activities across Africa since an early concern was 
that few clinical trials were being conducted across Africa (365, 366). This is beginning to change, 
building on examples in Burkina Faso, Kenya, Nigeria, South Africa and the WHO Solidarity Trial 
across several African countries (341, 367-369). By doing so, we believe we can support African 
countries’ efforts to continue to work together to tackle the pandemic, including jointly pursuing loan 
waivers to help protect against the financial consequences of COVID-19 (370, 371).  
 
This will be the first paper in this series as more information and findings become available. This 
builds on a recent systematic review regarding the importance of viral diseases in Africa, and the fact 
that different approaches will be needed across Africa to tackle COVID-19, depending on current 
circumstances (253, 372, 373). 
 
2. Methodology 
 
We adopted a mixed methods approach. This initially involved conducting a narrative review of the 
published literature as well as papers awaiting publication and internet references known to the co-
authors. We did not perform a systematic review. We were aware that some systematic reviews have 
already been conducted and published in this area including potential treatments despite the lack of 
data from robust clinical trials (21, 23, 33, 42, 66, 82, 114, 374-378). A number of the publications 
surrounding COVID-19 are also currently only available in pre-publication form and not peer-
reviewed. Alongside this, much of the information regarding ongoing activities across Africa are from 
internet sources, and it is too early to assess the impact of these, especially as COVID-19 cases 
appeared later in Africa than in either China or Europe.  
 
We also did not systematically review each paper for its quality using well-known scales such as the 
Newcastle-Ottawa scale or the Cochrane risk of bias tool as our emphasis was on contextualizing the 
findings rather than performing a systematic review (379-383). However, the publications and internet 
sources were filtered by the co-authors to add robustness to the present paper and its suggestions. 
 
In view of this, and to provide direction for the future, we supplemented information from the literature 
and internet sources with additional current information from co-authors across Africa. The co-authors 
include senior level personnel from governments and their advisers, lecturers and researchers from 
academia, and clinicians, as well as those involved with activities to enhance the rational use of 
medicine, undertake Health Technology Assessment (HTA), document medicine shortages, and 
involved with patient organisations from across Africa and wider. The co-authors were asked to 
provide information on the following themes or topics, where known, in their own country to 
supplement the ongoing literature: 
• Details about the current epidemiology of COVID-19 including CFRs, national responses to date 
and an assessment of the effectiveness, if known 
• The socio-economic impact as well as the impact on healthcare delivery in other priority disease 
areas including medicine and equipment shortages as well as attendance at clinics. This includes 
any information on the unintended consequences of COVID-19 in other disease areas if known 
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• How issues such as medicine shortages are being addressed and the implications for local 
manufacturing in the future 
• Current medicines and other approaches to treating patients with COVID-19 as well as ongoing 
studies that address issues such as false claims and hopes. In addition, ongoing activities to 
address falsified and sub-standard medicines 
• Key lessons for the future for all key stakeholder groups 
 
The same questions were asked of each co-author, with country-specific replies typically consolidated 
where there were multiple authors in a country. The information was subsequently consolidated by 
two of the authors (OOO and BG) and checked with each co-author during manuscript preparation to 
add robustness to the findings and suggestions.  
 
We also documented ongoing technology innovations across Africa, which we believe is important as 
Africa seeks to become self-sufficient in the management of patients with COVID-19 and beyond. 
 
Documented prevalence and mortality rates will typically be based on WHO date for consistency and 
reliability as there have been challenges with generating up-to-date data among a number of African 
countries due to the availability of testing facilities and testing kits, as well as concerns with some 
testing kits; however, as mentioned, this is now being addressed with the help of the WHO and others 
(242, 284, 297, 298, 384).  
 
The African countries chosen reflect a wide range of geographies and population sizes. We did not 
divide them into low- or middle-income countries as COVID-19 is likely to affect all African countries 
and they can learn from each other. 
 
Statistical analysis of the different measures and initiatives and their possible impact on the 
epidemiology, morbidity and mortality rates, has not been undertaken as this is too early given rising 
prevalence rates across Africa. In addition, our principal aim was to provide a comprehensive analysis 
of the current situation across Africa, including the potential implications for other infectious and non-
infectious disease areas within the African continent, to stimulate ongoing debates regarding potential 
future activities. This is important across Africa with high prevalence rates for both infectious and non-
infectious diseases, We have successfully used this dual approach in previous publications to 
stimulate debate in important healthcare areas and situations to provide future guidance as countries 
seek to improve the quality and efficiency of their approaches to medicine use, including during 
pandemics (168, 199, 257, 385-394). 
 
3. Findings  
 
The findings and activities are divided into sections to meet the study objectives. These include 
documenting the epidemiology among a range of African countries principally based on epidemiology 
data provided by the WHO. The aforementioned precedes discussing ongoing strategies to limit the 
spread of COVID-19 as well as their subsequent impact on morbidity and mortality in populations 
across Africa.  
 
The impact of COVID-19, including the unintended consequences on the healthcare system and 
patients, along with financial and socioeconomic issues, will be explored before documenting the 
subsequent impact on increased local production of pharmaceuticals and other supplies as well as 
any ongoing clinical studies and innovations across Africa aiming at improving future care. Finally, 
potential ways forward will be debated among all key stakeholder groups based on the experiences of 
the co-authors to provide future guidance. This includes key issues of shortages, unintended 
consequences, and misinformation as well as the role of patients and patient organisations in 
preventative measures and other interventions.  
 
3.1 Epidemiology 
There is considerable variation in the number of recorded cases, deaths and CFRs across Africa 
following the first reported case on February 14 2020 (233), with some countries yet to record their 
first deaths due to COVID-19 and some countries recording only a few deaths to date (Table 1), 
potentially reflecting different approaches and circumstances (Tables 2 and 2A). Table 1A in the 
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Appendix gives further details of the epidemiology over time as well as recovered cases where known 
and documented. 
 
Table 1 – Current epidemiology of COVID-19 (up to 30 June 2020) across Africa unless stated  
Country Population 
(2020) 
Number of 
Positive Cases 
Number of 
Deaths 
Case 
Fatality Rate 
(%) 
Algeria (276) 43,851,044 13907 912 6.6 
Botswana (276) 2,351,627 227 1 0.4 
Burkina Faso (276) 20,903,273 962 53 5.5 
Cameroon (276) 26,545,863 12592 313 2.5 
Democratic Republic 
of Congo (276) 
89,561,403 7039 169 2.4 
Egypt (5) 102,334,404 68311 2953 4.3 
Eswatini (Swaziland)  
(276) 
1,160,164 812 11 1.4 
Ethiopia (276) 114,963,588 5846 103 1.8 
Ghana (276) 31,072,940 17741 112 0.6 
Kenya (276) 53,771,296 6366 148 2.3 
Lesotho (276) 2,142,249 27 0 0.0 
Malawi (276) 19,129,952 1265 16 1.3 
Namibia (276) 2,540,905 203 0 0.0 
Nigeria  (276) 206,139,589 25694 590 2.3 
Rwanda (276) 12,952,218 1025 2 0.2 
Senegal (276) 16,743,927 6793 112 1.6 
South Africa (276) 59,308,690 151209 2657 1.8 
Sudan (5) 43,849,260 9258 572 6.2 
Tanzania (276) 59,734,218 509 21 4.1 
Uganda (276) 45,741,007 889 0 0.0 
Zambia (276) 18,383,955 1594 24 1.5 
Zimbabwe (276) 14,862,924 591 7 1.2 
NB: Population figures taken from Worldometer for Africa 2020 (395) 
 
3.2 Ongoing activities to address COVID-19 and their impact 
Different activities are ongoing across Africa to try and limit the impact of COVID-19. These are 
summarised in Table 2, with Table 2A in the Appendix giving additional details for those interested. As 
seen, prevention and treatment approaches remain broadly similar among the African countries, with 
a number of African countries combining approaches to provide joint guidance and updates on 
suggested activities, such as the East African Community (286). There are concerns though with 
limited activity in some countries, e.g. Tanzania, as well as fears that if lockdown measures are 
released too early due to financial and resource issues for citizens and governments these will 
appreciably enhance future prevalence rates (396). 
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Table 2 – Ongoing activities across Africa to help prevent the spread of COVID-19 including dates 
and examples 
 
Country Closing 
Borders/ 
Travel 
restrictions 
Quarantine 
Measures/ 
Testing 
measures  
Lockdown 
Measures 
Sanitary/ 
PPE 
measures 
Directives on 
Management 
and 
misinformation 
Algeria 17 March – 
closure of all 
land borders 
 13 March – 
Partial (capital) 
– full others with 
easing after that  
  
Botswana Ongoing 
restrictions on 
air travel and 
strict border 
controls (20 to 
28 March) 
14-day 
quarantine 
introduced and 
scientists 
trained on 
specimen 
collection (23 
March) 
Yes – including 
closure of 
educational 
institutions (18 
March) and 
general 
lockdown 
measures (2 
April) 
Mandatory use 
of face masks 
in public (May 
1) 
Yes – Directive to 
reduce 
misinformation 
with the potential 
for fines/ prison 
for abuse 
Cameroon 18 March - 
closure of 
borders  
3 March as 
well as active 
surveillance 
18 March - 
including school 
closures and 
ban on 
gatherings 
Yes- including 
encouraging 
hand washing 
and 
compulsory 
face masks in 
public (18 
March 
onwards) 
i) Establishing 
treatment centres 
ii) Encouraging 
household 
production of face 
masks  
Democratic 
Republic of 
Congo 
24 March – 
closure of all 
borders and 
travel 
(International 
and domestic) 
remain 
suspended (6 
June)  
3 March – 
Quarantine 
measures 
 
31 March – 
Curfew 
measures 
introduced with 
lockdown 
measures 
extended to 15 
May (2 May) 
Yes - 
Continued 
campaigns on 
prevention 
Instigation 
Community 
Action 
Committees 
Egypt 25 March – 
suspension of 
incoming 
passenger 
flights 
Yes – early 
testing of 
suspected 
cases 
25 March – 
Night time 
curfew and 
other lockdown 
measures 
Yes – 
Increasing 
public 
awareness of 
preventative 
approaches 
MoH developed 
standard 
treatment 
protocols 
Eswatini 
(Swaziland) 
27 March – 
Closure of 
borders 
27 March – 
Mandatory 
quarantining at 
borders and 
contract tracing 
introduced 
27 March –  
i) Partial 
lockdown and 
social distancing 
introduced 
ii) In addition, 
reduced 
numbers in 
omnibuses 
Yes – 
distribution 
PPE to all 
health facilities 
Yes – designating 
specific COVID-
19 hospitals and 
fines or prison for 
spreading 
misinformation 
(27 March) 
Ethiopia Closing 
borders (22 
March) and 
banning flights 
to more than 
30 countries 
(20 March) 
1 April – First 
testing labs 
(Northern 
Tigray Region)  
16 March - 
closing schools 
and banning 
large gatherings 
3 April – 
government 
and others 
helping with 
supply of PPE 
 
Ghana 22 March 
closure of all 
borders 
Enhancing 
testing facilities 
including 
16 March - 
Closure of 
schools and 
other measures 
Early April - 
Mandatory 
masks in public 
places in a 
Dedicated 
hospitals and 
Government fast 
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(quarantining 
from 16 March) 
suspected 
cases  
including 
restrictions on 
burials  
number of 
localities and 
patient 
education. 15 
June - 
Compulsory 
masks  
tracking testing of 
hand sanitisers 
Kenya 25 March 
suspending air 
travel and 
closing borders 
(mass testing 
and 
quarantining 
before this) 
Increasing 
testing facilities 
with the help of 
increased local 
production and 
mandatory 
quarantining 
13 - 19 March – 
lockdown and 
other measures 
introduced 
Mandatory 
wearing of face 
masks and 
increased 
public 
education 
i) Expansion of 
hospitals and ID 
units to deal with 
COVID-19 
ii) Development 
of treatment 
guidelines 
iii) Active 
programmes to 
address 
misinformation 
Lesotho 30 March – 
Borders closed 
Private industry 
and NGO 
support for 
testing 
30 March – 
lockdown 
measures 
introduced 
NGO and 
industry 
support to 
purchase PPE 
National 
response 
command centre 
provides 
guidance 
Malawi 1 April - 
suspension of 
international 
flights and 
increased 
surveillance 
Increasing the 
number of test 
facilities 
18 April - 
lockdown 
measures 
proposed but 
suspended 
Ongoing 
acquisition of 
PPE to meet 
demand 
Instigation of 
isolation centres 
for COVID-19 
patients and 
recruitment of 
more healthcare 
workers 
Namibia 15 March – 
International 
flights banned 
and 24 March 
Foreign 
travellers 
banned 
 14 March – 
banning large 
gatherings; 15 
March – schools 
closed and 27 
March – 
lockdown 
measures 
introduced 
Individuals 
expected to 
wear masks in 
public  
Establishment of 
isolation units in 
public hospitals to 
tackle severe 
cases 
Nigeria 23 March – 
closure of 
borders and 
ban on flights 
Protocols for 
testing to 
increase rates 
23 March – 
closure of 
schools and ban 
on gatherings; 
30 March – ban 
on non-essential 
travel 
Measures 
include hand 
sanitisation 
and mandatory 
wearing of 
masks (23 
April) 
Nigerian CDC 
developing 
protocols and 
case 
management and 
instigation of 
isolation centres 
Rwanda 21 March – 
Ban on travel 
including air 
travel 
Rapid testing – 
speeding up 
identification of 
cases  
Mid-March – 
lockdown 
including 
unnecessary 
travel outside of 
homes 
prohibited 
19 April - 
Wearing of 
masks 
compulsory 
early in the 
pandemic 
Robots are 
helping in 
hospitals to 
address resource 
and other 
concerns 
South Africa 26 March – 
complete travel 
ban introduced 
(eased 4 May) 
April – mass 
screening 
introduced as 
well as active 
case-finding 
26/ 27 March – 
Stage 5 
lockdown 
introduced 
including school 
closures 
Early April – 
use of PPE/ 
hand sanitisers 
regulated 
i) Isolation 
centres 
established 
ii) Spread of 
misinformation 
punishable with 
fines or prison 
iii) Length of 
prescriptions 
increased  
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Sudan Early March – 
Travel 
restrictions 
introduced – 
extended 20 
April 
Screening at 
point of entry 
and WHO/ 
UNICEF 
helping with 
testing 
materials as 
currently 
limited 
Early/ Mid-
March and 
extended - 
social isolation 
and school 
closures 
WHO/ UNICEF 
helping with 
PPE – 
concerns with 
appreciably 
increased 
prices in shops 
One isolation and 
treatment centre 
in the capital  
Tanzania April 12 – 
International 
flights 
suspended 
23 March – 
14-day 
quarantining 
from some 
countries 
Yes – for large 
gatherings – 
however 
concerns that 
largely ignored 
 12 May – WHO 
helping to 
convert a 
commercial site 
into a 500-
bedded 
treatment 
centre 
Uganda 20 March – 
Closing 
borders and 
banning 
international 
travel 
20 March – 
Mandatory 
quarantine at 
own expense 
for returning 
personnel 
20 March – 
Lockdown 
measures 
implemented 
including 
suspending 
markets– 
slowly 
releasing Mid 
May 
Advising the 
public 
regarding 
hygiene 
measures 
Mandatory 
wearing of 
masks 
Task Force 
initiated 
(national, 
regional, 
district) to 
provide 
guidelines 
Zambia March - 
Temporary 
closing of 
borders 
especially 
with Tanzania 
i) Initial 
response 
included a 
14-day 
quarantine for 
travellers 
(Mid-March) 
ii) Mass 
screening 
where cases 
identified as 
well as 
contact 
tracing 
Lockdown 
measures 
including 
social 
distancing and 
closure of 
educational 
establishments 
March - 
Mandatory 
wearing of 
masks in 
public places 
and active 
procurement 
of PPE 
MoH training 
and recruiting 
health workers 
to help with 
case 
management 
3 designated 
laboratories to 
help with testing 
using PCR 
methods  
Zimbabwe 31 March – 
closure of 
borders 
31 March - All 
returnees 
quarantined 
for 21 days 
30 March 
national 
lockdown – 
further 
extended 1 
May 
Local 
production of 
PPE and 
hand 
sanitisers to 
address 
shortages 
i) Establishment 
of COVID-19 
Treatment 
Centres at one 
ID Hospital in 
Harare and one 
in Bulawayo 
ii) National 
Guidelines 
update 
iii) Law passed 
with potentially 
prison for fake 
news 
 
3.3 Health and social impact of COVID-19 including impact on other diseases 
Measures to limit the spread of COVID-19 are having a considerable impact on other disease areas 
including both infectious and non-infectious diseases. Table 3 contains details of the considerable 
healthcare and financial impact of COVID-19 as well as ongoing activities among African countries to 
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address these. We will be examining unintended consequences in more detail in future research 
projects. Similarly, there are considerable financial and socioeconomic consequences which are also 
being addressed, with countries having the opportunity to learn from each other 
 
Table 3 – Healthcare, financial and socioeconomic impact of COVID-19 across Africa 
 
Country Healthcare, Financial and Socioeconomic impact 
Botswana • To date: 
o Healthcare services have not been seriously affected by the 
COVID-19; however, in ambulatory care there are fewer 
attendances at outpatients’ clinics due to a bar on public transport   
o here has been no noticeable impact on immunization programmes, 
prevalent infectious diseases (TB and HIV) and NCDs 
o However, increased level of suspicion of COVID-19 in people 
presenting with respiratory illnesses 
Cameroon Healthcare concerns include: 
• Cameroon is marked by violence in the North, the North West and the 
South West regions with a considerable number of internally displaced 
persons (IDPs). The COVID -19 pandemic constitutes an additional strain 
on the country’s resources, which is a concern for the refugee populations. 
• The implementation of both WHO-advised basic protective measures and 
national strategies have been slow especially in the crisis hit regions of the 
country due to other humanitarian crises with IDPs. However, with the 
WHO stating cloth masks should be used, this has made it easier for a 
majority of the population to be able to afford a mask. 
• Treatment centers are currently lacking ventilators 
• Cameroon reported three outbreaks of monkey pox between 2018 and 
2020, several cholera outbreaks, measels, and polio between 2016 and 
2020, with concerns for these infectious disease areas with increasing 
focus on COVID-19 (397-402) 
• However, International humanitarian agencies such is the Médecins Sans 
Frontieres (MSF) are forefront in the fight against COVID-19 in the crisis 
ridden region 
Financial and socioeconomic concerns and ongoing strategies to address this 
include:  
• The imposed lock down has led to a drastic reduction in economic 
activities, shortfalls in tax and non-tax revenues with a looming budget 
deficit.   
• To help address concerns the government:  
• Is embarking on delays in debt servicing and informing its creditors and 
international partners of its inability to meet current financial commitments 
• Shutting down businesses or other penalties selling basic commodities at 
increased prices or hoarding commodities to create artificial shortages to 
profiteer 
•   
• Despite these measures, over 92% of businesses, mostly small and 
medium size, are projecting appreciable downsizing of employees with the 
possibility of over 50% of companies collapsing in 3 months in the event of 
an extension of the current lockdown Despite the desire to sustain 
schooling through on-line classes, the poor infrastructure, low internet 
penetration rate, limited and fluctuating bandwidth has made this 
endeavour almost impossible for most academic establishments. 
Consequently, new approaches are needed 
Democratic 
Republic of 
Congo 
• An ongoing concern is that COVID-19 outbreak is creating significant 
additional pressure on an already overburdened health and social 
service delivery system in one of the world’s poorest countries, which is 
exacerbating the vulnerabilities of the population (403, 404) 
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• This builds on an epidemic of measles, with the number of deaths to date 
appreciably higher than seen with COVID-19. Ducomble et al. in their 
recent paper documented 311,471 reported cases following the outbreak in 
2019 with 6045 reported deaths mainly among children under 5 (405) 
• In addition, the Republic has had to deal with its tenth outbreak of Ebola, 
which has been ongoing since August 2018, the largest-ever outbreak 
reported in the Republic and the world's second largest, with a Public 
Health Emergency of International Concern declared on 17 July 2019 (406) 
• There is ongoing testing against Ebola in the Republic, e.g. from 15 to 21 
April 2020, an average of 2037 alerts were reported and investigated per 
day, which is ongoing Of these, an average of 196 alerts were validated as 
suspected cases each day (407) 
• Overall, the WHO reported as of 21 April 2020, a total of 3461 cases of 
Ebola in the Republic, including 3316 confirmed and 145 probable cases, 
of which 2279 patients have died giving an overall case fatality ratio 66%. 
Out of the total confirmed and probable cases, 56% were female and 28% 
were children (407) 
Egypt Healthcare concerns include: 
• All outpatient services closed and services limited to emergencies including 
surgeries. There is also shortage of blood for transfusion and ICU beds for 
non-COVID-19 patients 
• Many departments/hospitals closed due to COVID-19 infections; however, 
reopened after decontamination procedures 
• Shortage of PCR testing kits to adequately test the population 
 
Alongside this: 
• Ongoing fear that the virus spreads from the dead bodies of infected 
COVID-19 patients leading to the abandonment of corpses of some 
infected doctor/patients despite undertaking all recommended preventive 
measures 
• Stigma for medical doctors working in the diagnosis of asymptomatic cases 
due to a misconception that they are source for virus transmission 
 
Financial and socioeconomic concerns and ongoing strategies to address this 
include:  
• Paid leave to government employees with special conditions including a) 
Women with children less than 12 years old, b) Employees who have 
documented chronic disease/s, c) Employees who have been in contact 
with COVID-19 patients and d) Employees who return from travel outside of 
Egypt    
• Monthly financial support to people with irregular employment (408). 
Similarly, some NGOs have helped people in this category with supply of 
daily needs 
• The Government on 20 April announced 100 billion EGP (USD 6.4 billion) 
to fund a comprehensive plan to combat the pandemic, half of which is 
allocated to the tourism sector (408) 
Eswatini 
(Swaziland) 
Health care concerns include:  
• The designated isolation Hospital is currently not able to accommodate 
more than 16 patients. To address this, the Government has dedicated 
some hotels for quarantining; however, there are concerns with availability 
and patients are currently being quarantined at crowded homes. Hospitals 
are also being encouraged to make plans for isolating unstable suspected 
cases; however again concerns with capacity  
• Partial closure of the major private hospital in Mbabane affecting care 
• Very few ventilators were functional in government health facilities during 
the early stages of the pandemic with more needed as well as a shortage 
of hand sanitisers (although being addressed with local production) 
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• Adequate management of patients with HIV and TB in Eswatini, which has 
the highest percentage of people living with HIV worldwide, and a high 
prevalence of TB and with approximately 70% of all TB patients co-infected 
with HIV(409, 410). To help reduce visits, typically stable HIV patients now 
receive six-monthly refills of ARVs and among those with TB, medication is 
provided for one to three months depending on their health and drug 
availability (410) 
• Given the risk of COVID-19, every effort should be made by hospitals and 
health centre staff to down-refer patients with stable NCDs to the primary 
care level. Patients with unstable diseases, recent emergencies related to 
their condition, and/or paediatric patients, are encouraged to come to 
hospital clinics where possible. All patients in primary care should only be 
administered with a one-month refill to enhance attendance and follow-up 
• Encouragingly, vaccination programmes have not been stopped although 
due to travel restrictions there are missed appointments. There are also 
concerns with the availability of the influenza vaccine in retail pharmacies 
with out-of-stock situations reported from 23 April 2020 
 
Financial and socioeconomic concerns and ongoing strategies to address this 
include:  
• SRA-COVID-19 E90 million tax relief fund for small and medium 
enterprises 
• Zimbabweans in Eswatini have donated E10000 towards the COVID-19 
Fund 
• Businesses in Eswatini have donated E24 million towards the COVID-19 
Fund 
• The Banks have announced that those individuals and companies that 
need short term financial support or relief can approach them and each 
application will be assessed on a risk-based approach. In addition, the 
Central Bank had made provisions for businesses to obtain loans at lower 
interest rates to help out (411) as well as encouraging electronic payments 
rather than cash transactions 
• The Eswatini Government providing food assistance to the most vulnerable 
adversely affected by the COVID 19 pandemic, which will benefit over 
300,000 individuals from 63,000 households across all four regions of the 
Kingdom (412) 
• Such measures will help address the potential for an appreciable number of 
companies laying off staff due to the virus (413) 
Ghana Healthcare concerns include: 
• An outbreak of meningitis in the Upper West region of the country which 
has killed 33 people as of 4 April had not received the same attention as 
COVID-19 (414). By early May, 40 deaths had occurred and over 400 
cases recorded, with mass vaccination now being contemplated 
• Vaccination programmes including polio vaccination ceased early during 
the lockdown; however normal vaccination programs for babies born in 
hospitals are still being administered 
• Currently no routine follow-up of patients with NCDs 
• Psychologically, the lockdown has given a sense of imprisonment 
potentially enhancing the prevalence of mental health disorders. However, 
evening exercise and training under the cover of darkness has increased to 
help address this 
• Public healthcare systems have focused mainly on COVID 19 cases during 
the lockdown, with a shift in funding to tackle COVID-19 to the detriment of 
other disease areas 
 
Financial and socioeconomic concerns and ongoing strategies to address this 
include:  
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• Free food distribution by the Government and NGOs to those in need, 
initially free transport for health workers, as well tax rebates for frontline 
workers. In addition, a 50% reduction in electricity and water tariffs and 
donation of salaries by Government officials as well as the Ghana Chamber 
of Mines to the COVID-19 National Trust Fund (415, 416) 
• Religious organisations have donated beds and monies to the National 
Trust Fund (417, 418) 
• The World Bank has provided US$100 million to assist in tackling the 
effects of the COVID-19 pandemic (419) 
 
A recent publication regarding the cost-benefits of moderate social distancing in 
response to the COVID-19 pandemic in Ghana suggests that the costs 
outweigh the benefits. Consequently, the authors believe there is an urgent 
need to avoid escalating social distancing policies in Ghana, re-open schools 
and avoid reducing healthcare activities in other infectious diseases apart from 
COVID-19 as well as  NCDs (420) 
Kenya Healthcare concerns include: 
• Reduced access to other healthcare services with most hospitals focusing 
on COVID-19, and currently no mechanisms for the management of 
chronic illnesses for those who are in quarantine. However, the rise in 
telemedicine approaches could help with identification and management of 
diseases (208, 421, 422) 
• Public health workers and community health volunteers have been 
mobilised and engaged to help with COVID-19 prevention 
• A reduced flow of patients with other disease. To address this, online 
consultations have been promoted and some patients including those with 
cancer have received letters permitting them to travel and there has been 
an increase in home deliveries of medicines 
• Some quarantine centres do not have adequate facilities for social 
distancing and infection prevention and control. In addition, concerns about 
the ability to pay for quarantining (423) 
• COVID-19 positive cases have been reported in densely populated areas 
such as slums and refugee camp (Kakuma) putting strain on the public 
health programmes (424) 
• Response to other infectious diseases, e.g. cholera outbreak in Eastern 
and North Eastern Kenya - although systems have now been put in place 
to avert further loss of life (425). At least 194 lives have also been lost and 
many people displaced following heavy floods in Western Kenya in April 
putting further pressure on healthcare systems (426) 
• Antenatal and postnatal programmes have also been affected in some 
areas in Kenya 
• Encouragingly, vaccination programmes are ongoing with no adverse 
impact reported to date. 
 
Financial and socioeconomic concerns and ongoing strategies to address this 
include:  
• US$50 million donation from the World Bank to Kenya to tackle the COVID-
19 pandemic (427), with donations also from other countries (428) 
• Citizens earning less than US$300 per month have been exempted from 
paying taxes, with a general reduction in income tax. In addition, reduction 
in VAT, expedition of VAT payments and a general increase in cash flows 
especially for businesses (429)  
• Tax relief on telecommunication and other essential services as well as 
lowering of interest rates (429) 
• Food distribution to the vulnerable and low socioeconomic income groups 
• Money retrieved from corruption cases will also be used to fund COVID-19 
activities  
Lesotho Healthcare concerns include: 
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• There are only two hospitals designated for COVID-19 patients in Lesotho 
with limited number of beds and a limited number of ventilators for the 
entire country 
• The government has though prepared a number of guest houses and 
hotels as quarantine facilities for people coming from other countries, who 
are screened for 14 days  
• Screening has been scaled up at all of borders since there has been an 
influx of people entering the country through illegal borders. Screening is 
also being conducted in healthcare facilities and in the communities.  
• Initially, there were inadequate laboratory services in Lesotho, and COVID-
19 tests were undertaken in South Africa. However testing has now started 
in the National Reference Laboratory (430) with a substantial contact 
tracing program in place in response to the escalation of COVID-19 cases 
• Currently, there are no reports on the impact of COVID-19 on the 
management of other infectious and non-infectious diseases, no identified 
medicine shortages, and vaccination programmes are progressing as 
normal. However, there are issues with accessing services due to 
shortages of public transportation and travel restrictions  
• There has been considerable misinformation surrounding COVID-19 which 
may negatively hamper the government’s efforts to contain the disease and 
prevent its spread. The Ministry of Health is working hard to deal with this 
and have quickly reprimand perpetrators   
Financial considerations: 
• A concern is that prices of some basic food commodities, disinfectants and 
cleaning supplies have increased. However, the government has promised 
financial support where necessary 
Malawi Healthcare concerns include: 
• Additional strain on the HCP workforce to cover all disease areas and not 
just COVID-19 patients 
• Limited supply of PPE has put the lives of HCPs in danger, which resulted 
in a strike in many facilities across the country. This has been addressed 
by employing more HCPs and increasing their risk allowances (431), as 
well as making more PPE available. UNICEF has helped procure PPE 
(432) and the Jack Ma and Alibaba foundations have also helped to 
address supply issues (433) 
• The shortage of essential PPE for citizens has been compounded by an 
escalation of prices with the Competition and Fair Trading Commission 
(CFCT) of Malawi conducting price checks to help address concerns (434) 
• The shortage of hand sanitizers has been solved helped by the local 
production of hand sanitizers by many companies including institutions of 
higher learning in addition to supplies with the help of UNICEF. However, 
this has resulted in regulatory dilemma with limited availability of testing 
tools and protocols for such products. Measures are now in place in both 
the short term and long term to help solve this problem 
• A major concern is that concentration on COVID-19 has diverted attention 
away from ensuring the availability of essential medicines for other disease 
areas 
 
Financial and socioeconomic concerns and ongoing strategies to address this 
include:  
• Cash payments to the poor to help them survive the lockdown (435) 
• The United Nations launching an emergency appeal in Malawi. The UN 
believe US$140 million is needed to support the country's preparedness 
and response for the next six months (May onwards) and target the most 
vulnerable, which equates to 7.5 million people, nearly half of the country's 
population, with approximately 70% of the population living below the 
international poverty level if $1.90/ day (436) 
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• The government has reduced the cost of fuel to mitigate against the 
increase in the cost of transport, which resulted from a reduction in the 
number of people boarding minibuses and private cars leading to an 
increase in the cost of transport and transporters overcharging passengers 
to make up for reduced numbers (437) 
• Schools have been closed since 23 March 2020 (438), with calls for 
alternative ways of engaging students including home reading and online 
learning; however concerns with limited resources including computers 
Namibia • Healthcare concerns include a lack of hand sanitisers. Consequently, the 
School of Pharmacy at the University of Namibia was been tasked to 
produced hand sanitizers for the Ministry of Health and Social Services and 
other governmental and non-governmental organisations 
• Measures to address financial and socioeconomic consequences 
include: 
o Over 8 billion Namibian Dollars have been committed by the 
Government to stimulate the economy, provide social protection 
to families and support health sector response (439) 
o The government through the Ministry of Finance has also given 
financial support to small/individual business owners who 
depended on their daily income for survival. The package was 
~USD 47 per person 
Nigeria Healthcare concerns include: 
• Most secondary and tertiary public hospitals have shut down routine 
outpatient services with most elective surgeries on hold; however, facilities 
to interact with physicians when the need arises are being put in place 
including telephone services 
• Re-organisation of duty and call roasters to minimize the number of 
healthcare workers exposed to COVID-19 at any one time 
• Immunization clinics are continuing to function as an essential service 
endorsing advice from the WHO (440); however, utilization has reduced 
due to the lockdown  
• Many patients suffering from non-COVID-19 conditions are currently unable 
to readily access care leading to concerns with increasing inactivity as well 
as increased use of complementary and alternative medicines  
• Identification and management of NCDs has been hampered by reduced 
access to healthcare facilities, likely to impact negatively on medication 
adherence and outcomes, exacerbated by concerns with drug shortages  
• Increasing levels of depression/ domestic violence as the lockdown and the 
lack of money continues 
• Nigeria is currently experiencing an outbreak of Lassa fever with 979 
confirmed cases as at 18th April 2020 in 27 out of the 36 states leading to 
188 deaths with a case fatality of 19.2% (441); however, receiving less 
attention than COVID-19 
 
Financial and socioeconomic concerns and ongoing strategies to address this 
include:  
• Tax rebates of 50%, suspension of import duties on medical equipment, 
medicines and PPE for treatment and management of COVID-19 for three 
months, effective 1 March 2020 
• N1 trillion (over US$2.5 billion) in loans to boost local manufacturing and 
production across critical sectors  
• Distribution of cash to the most vulnerable poor and families in various 
communities. 
• On April 1st, the Nigerian Electricity Regulatory Commission (NERC) 
suspended the payment of the new electricity tariffs scheduled to 
commence on April 2nd, citing poor electricity supply, wide metering gap 
and the impact of the COVID-19 pandemic as the basis for this gesture 
South Africa Healthcare concerns include: 
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• Elective surgeries have been stopped, with hospitals typically only dealing 
with emergencies 
• There are ongoing programmes to educate the public on the importance of 
avoiding going to high level hospitals to reduce congestion. Overall, 
hospitals and clinics appear to be functioning although support staff such 
as HR, finance and some other allied staff have been sent home for 
lockdown to avoid transmission  
• Access to health facilities has also become a major challenge due to lack of 
public transportation during lockdown 
• To address concerns with the supply of medicines especially for patients 
with chronic conditions, a greater supply of medicines has been given to 
patients to avoid repeated visits to facilities and also includes prescriptions 
filled for up to four months or longer (205, 442) 
• Currently, though there appears to be no shortages for possible treatments 
– helped by the lack of endorsement of medicines used to treat malaria or 
HIV to treat COVID-19 by the South African Health Products Regulatory 
Authority with concerns about stockpiling of medicines and lack of evidence 
(108). The South African Pharmacy Council also sought to discourage 
stockpiling of essential medicines (443). However, shortages are likely to 
occur as the pandemic continues; with ongoing steps to try and reduce this 
address this (315, 316) 
• There are concerns with the decrease in the extent of HIV testing as well 
as collection of ARV’s due to fears of contracting COVID-19 (193) 
• There are concerns with vaccination programmes with April 2020 showing 
a 22% decreases in the measles first dose and in fully immunised children 
under one year (173), with UNICEF South Africa generally urging parents 
and caregivers to get their children immunized (444). Where immunisation 
services have been curtailed, the risks of children dying from a vaccine-
preventable disease appreciably outweigh their risks of dying from COVID-
19 (172) 
• Increased anxiety among citizens as seen with protests in some Provinces 
against housing of citizens who were repatriated from China  
 
Initiatives to address financial and socioeconomic issues include: 
• The World Bank, International Monetary Fund, BRICS New Development 
Bank and the African Development Bank have been approached and are 
working with the National Treasury on various funding projects (445) 
• Tax relief, release of disaster relief funds, emergency procurement, wage 
support, funding to small businesses 
• Social relief of distress grants given to those above 18 years of age who 
are (445, 446): (i) Unemployed; not receiving any income or social grant; 
(ii) any unemployment insurance benefit, any stipend from the National 
Student Financial Aid Scheme or resident in a government funded or 
subsidised institution 
• Other initiatives include:  
o child support grant beneficiaries will receive an extra R300 in 
May and from June to October 2020 they will receive an 
additional R500 each month 
o all other grant beneficiaries will receive an extra R250 per 
month for the next six months; a special Covid-19 Social Relief 
of Distress grant of R350 a month for the next 6 months will be 
paid to individuals who are currently unemployed and do not 
receive any other form of social grant or Unemployment 
Insurance Fund payment, and grants increased for a number 
of categories s of 1 April 2020 
• There has also been roll out food assistance through vouchers and cash 
transfers. The Department of Social Development has also partnered with 
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the Solidarity Fund, NGOs and community-based organisations to 
distribute 250,000 food parcels across the country 
• The Minister has also granted limited-time block exemptions to healthcare, 
banking, retail property and hotel sectors in respect of certain categories of 
agreements or practices between participants from the application of 
Section 4 (restrictive horizontal practices between competitors) and Section 
5 (restrictive vertical practices between participants at various levels of the 
supply chain) of the Competition Act (447) 
Sudan Healthcare concerns include: 
• Difficulty with accessing Primary Health Care (PHC) for the treatment of 
NCDs services including renal dialysis due to the partially paralysed 
activities in the public and private sectors 
• Health centres/ hospitals closing down once a case is suspected or 
confirmed with isolation of all health care providers who came into contact 
with the patient 
• Inadequate supply of PPE for healthcare workers resulting in a good 
proportion on quarantine and a great reluctance among others to continue 
to work under the prevailing conditions. To help address this, there has 
been a shipment of 20,000 testing kits, 100,000 masks and 1,000 
protective suits from the Jack Ma Foundation (448), and UNICEF has 
mobilized US$370,000 for Infection Prevention and Control (IPC) supplies 
for use at points of entry to Sudan and ambulances (448) 
• Economic hardship with long queues at bakeries and oil stations make 
social distancing difficult and meaningless 
• Access to immunization services has been reduced in view of additional 
resources for COVID-19 
• The Federal Ministry of Health together with the WHO has developed a 
US$76 million countrywide COVID-19 preparedness and response plan to 
help combat concerns and the spread of the virus (448) 
 
Financial and socioeconomic concerns and ongoing strategies to address this 
include:  
• The harsh socioeconomic impacts of the pandemic are further 
compounded by the prevailing Sudanese Revolution and its attendant 
political and leadership crisis as well as Sudan still on the American State 
Sponsors of Terrorism list  
• Sudan is on the list of countries expected to have severe food shortage 
from COVID-19 with already 61% of the population in South Sudan in a 
state of food crisis in 2019 (449), with general agreement that the nation 
cannot sustain long-term lockdown and movement restriction with limited or 
no organized efforts from government to meet basic needs 
• However, the World Bank on April 6 activated the Contingent Emergency 
Response Implementation Plan (CERIP) providing US$7.6 Million in 
support of the coronavirus emergency response (450) 
• In addition (451): 
o The Islamic Development Bank donated US$50 million to Sudan’s 
Health Ministry for the Covid-19 response 
o The United States announced on 27 March a donation of $8 million 
to Sudan. This assistance will primarily provide health-related 
support and supplies to bolster water, sanitation, and hygiene 
activities 
Uganda Healthcare concerns include: 
• Difficulties with patients accessing ambulatory care facilities with 
restrictions on public and private transport alongside the curfew  
The Government has urged the public not to relax efforts to reduce HIV/ 
AIDS with the current high focus on COVID-19, with the aim of ending 
AIDS as a public health threat by 2030 (452),  some patients with HIV will 
struggle to obtain their medicines. This is being addressed to some extent 
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by volunteers and the Ministry allowing community health workers to pick 
up medicines for patients (453)  
• Ensuring the safety of patients in health facilities and quarantine centres, 
enhanced by lack of testing facilities 
 
Measures to address financial and economic considerations include: 
• The Ugandan president warning traders against raising the price of goods 
because of COVID-19 infection; however, Uganda currently has no price 
control and anti-profiteering laws (454) 
• Seeking support from the International Monetary Fund (IMF) as well as 
concessional loans amounting to US$100 million for 2019/ 2020 and 
US$90million 2020/ 2012 from the World Bank and seeking export 
promotion strategies to address concerns with high import rates (455) 
• Early May, the IMF approved a US$491.5 Million Disbursement to Uganda 
to help address the financial impact of the COVID-19 pandemic (456) 
• Mobilisation of funds from the general public fund to help address the 
financial consequences 
Zambia Healthcare concerns include: 
• HCPs are already overcommitted providing services to high patient loads 
afflicted with other infectious diseases and NCDs. To address this, the 
Government has committed to recruiting an additional 8,000 health workers 
in 2020 to meet its target of enlisting 30,000 health workers by 2021 (457) 
Inadequate supply of commodities and equipment. To address this, the 
government has suspended custom duties and VAT on additional medical 
supplies used for COVID-19 coupled with donations from external 
organisations (458-460) 
• Encouragingly, routine ambulatory and hospital care services in most parts 
of Zambia remain functional and routine vaccination programmes 
(especially for childhood illnesses) have not been disrupted in most parts of 
Zambia 
• However, the financing of healthcare is already a concern and anticipated 
to be further constrained by the COVID-19 pandemic should further flare 
ups occur. This will negatively impact on care generally  
 
Financial and socioeconomic concerns and ongoing strategies to address this 
include:  
• Epidemic Preparedness Fund amounting to ZMW57 million (approx. 
US$3.1 million); Cabinet approving a COVID-19 Contingency and 
Response Plan with a budget of ZMW659 million (approx. US$36.2 million) 
under the Disaster Management and Mitigation Unit (DMMU); and the 
Government mobilizing funds through the budget and engagement with 
international and domestic stakeholders (461) 
• Easing liquidity; waiver of tax penalties and interest on outstanding tax 
liabilities resulting from COVID-19; building new and sustainable value 
chains and engaging multilateral organizations including the IMF and the 
World Bank (462) 
Zimbabwe Healthcare concerns include: 
• Accessing healthcare for other conditions especially for chronic NCDs has 
become more challenging  
• Patients with fever are also not getting appropriate timely care because 
health workers are not comfortable managing them until they know their 
COVID-19 status. This has resulted in some avoidable complications 
building on the malaria outbreak with over 226 deaths reported since 1 
January 2020 (463, 464). Consequently, there is a need in malaria areas to 
differentiate malaria from COVID-19  
• There has been an alteration of drug dispensing protocols for patients with 
NCDs who are stable to provide these for 3-6 months to minimize hospital 
visits. The same principles also apply to patients on treatment for TB and 
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HIV. However, Zimbabwe had a challenge with the shortage of medicines 
to treat patients with NCD even before the COVID-19 pandemic. Most of 
the medicines for NCDs are typically procured out-of-pocket, with patients 
told to continue sourcing from private pharmacies if the hospital pharmacy 
does not have the medicine 
• This is a potential shortage generally in supply and access to medicines 
especially with an increase in malaria cases amid the COVID-19 pandemic 
• The plans for mass campaigns for TCV/IPV/HPV/Vitamin A that was 
scheduled for May 2020 has been put on hold due to the pandemic. 
Vaccination though is ongoing at facilities building COVID-19 guidance 
(social distance at facilities). However, this is a challenge when there is a 
need to ensure vaccination occurs in batches and where there are issues 
with public transport 
 
Measures to address financial and socioeconomic consequences include 
freezing of prices for basic commodities including food and income support 
 
3.4 Shortages of medicines and activities to address this 
There are shortages of medicines across Africa, as most medicines are imported (Table 3A). We are 
likely to see local production increasing as part of future strategies to address ongoing shortages as a 
result of COVID-19, and we will be monitoring this in the future. 
 
Table 3A in the Appendix contains details of ongoing shortages across Africa with countries starting to 
implement robust strategies to help deal with these in the future.  
 
3.5 Clinical trial activities 
As mentioned, there has been limited clinical trial activity across Africa compared with higher income 
countries; however, this is beginning to change: 
• In Botswana, there are currently no on-going clinical trials on COVID-19; however, the University 
of Botswana (a government-funded institution) has called for proposals on COVID-19 research, 
which was open until May 15, 2020 
• Egypt appears to be undertaking several clinical trials with currently 14 registered clinical trials 
granted expedited approval by review boards utilizing different medicines and treatment 
modalities (465) 
• Currently there are no known clinical trials commissioned in Eswatini with no demonstrable 
commitment to commissioning COVID-19- related clinical research activities given the current 
pressure on resources 
• In Ghana, there currently appears to be no clinical trial research activities related to COVID-19. 
However, some medicinal plants with potential antiviral activity have been identified and 
submitted to the Centre for Scientific Research into Plant Medicine and Noguchi Memorial 
Institute for Medical Research for the commencement of studies/screening on their potential 
therapeutic anti-COVID-19/SARS-CoV-2 activities 
• Kenya is currently involved in WHO clinical trials for three medicines used in combating COVID-
19. A vaccine clinical trial is envisaged in the next two or three months at the Kilifi 
KEMRI/Welcome Trust collaborating research site. The Institutional Review Boards have 
established electronic systems for protocol submissions and review feedback and expediting the 
review process to (3-4 days for first response) facilitate implementation. 
• Three clinical trials have been registered in Nigeria but currently none have started recruiting 
(466). However, Nigeria has been included in the WHO SOLIDARITY trial with five treatment 
centres participating 
• A number of clinical trials are currently ongoing in South Africa for both pharmaceutical and non-
pharmaceutical interventions with the Institutional Review Boards in South Africa having 
established electronic systems and expediting review process to facilitate these. This includes the 
SOLIDARITY WHO trial with the South African research team being led by senior academics and 
clinicians from eight medical schools (467) as well as the BCG vaccination trial programme for 
healthcare workers (468) and the South African Ox1Cov-19 Vaccine VIDA-Trial, the first clinical 
trial for a vaccine against Covid-19 in South Africa with the first patients enrolled the week of June 
23 2020 (469, 470). 
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• Zimbabwe is also involved in the WHO SOLITARY Trial  
 
3.6 Technical innovations regarding COVID-19 from across Africa 
There are many ongoing innovations across Africa to tackle COVID-19, and these are expected to 
continue. In Senegal, the Institut Pasteur, with support from the WHO, developed a USD1 COVID-19 
Rapid Testing Kit to enable the country to undertake considerable testing with the government 
currently seeking approval for their kits to be used in other African countries (471-473). Scientists and 
industry partners in Ghana have also developed a test for COVID-19, a finger-prick blood test to 
rapidly detect antibodies, which is seen as beneficial among asymptomatic cases to reduce the 
spread (267).  
 
Students at the Jomo Kenyatta University of Agriculture and Technology in Kenya developed a Mobile 
app to help with contact tracing, triaging and case management of COVID-19 patients (474), with 
other students in Kenya also developing and making ventilators to address shortages (268, 475, 476). 
A multidisciplinary team at Wits University in South Africa used their design and engineering skills to 
create face shields (477). A multi-disciplinary team from Honoris United Universities from across 
Africa, including doctors, engineers, and students, have developed a prototype for a new non-invasive 
respirator alongside face shields and splash protection masks, which can be quickly and affordably 
manufactured via 3D printing to address current shortages (269).  
 
Scientists in Uganda have also developed hand-free hand sanitisers and rapid testing kits with a team 
at Makerere University involved in manufacturing low-cost ventilators to bolster the country’s capacity 
in case demand increases (478-480). 
 
The Gauteng Department of Health in South Africa has introduced an app (Mpilo) based platform that 
supports improved service delivery and improved patient experiences in Gauteng Health facilities 
(481). The University of Pretoria in South Africa has also produced an interactive app with real-time 
data on COVID-19 infections to help with management (482). The governments in Egypt and Ghana 
have also recently launched apps to help with tracing people who have come into contact with 
COVID-19 positive patients as well as provide advice on management (483, 484).  
 
Scientists in Ghana have also successfully sequenced the genomes of SARS-COV-2 from 15 of the 
samples obtained from confirmed COVID-19 cases through active collaboration using the Next 
Generation Sequencing (NGS) Core and High-Performance Computing system (485). Whilst there 
have been some differences in the strains between countries, all 15 genomes typically resembled 
(>92% similarity) the original strain isolated from China (485). Scientists from the Nigerian Centre for 
Disease Control (NCDC) and others from across Nigeria, including from Lagos University Teaching 
Hospital, have also reported sequencing of the SARS-CoV-2 from the first confirmed case of COVID-
19 in Nigeria (486).  
 
3.7 Key lessons among individual African countries and implications for the future for key 
stakeholder groups 
Table 4A (Appendix) summarises key lessons learnt among a number of African countries going 
forward in the management of COVID-19 and other disease areas based on their experiences.  
 
Boxes 1 to 6 consolidates potential activities that could be undertaken across Africa to improve the 
future care of patients with COVID-19 building on existing activities (Tables 2 and 2A). However, we 
need to be mindful of a range of healthcare issues including the unintended consequences on both 
health and socioeconomic circumstances. This builds on Tables 3, as well as 3A and 4A, for 
individual African countries as well as recommendations for all key stakeholder groups in Africa going 
forward in the management of both infectious and non-infectious diseases as well as clinical and 
economic issues surrounding fixed dose combinations (168, 198, 199, 257, 487). 
 
A key area will be patients especially in view of their necessary compliance with any lockdown and 
social distancing activities as well as considerations for the unintended consequences of COVID-19. 
These include mental health considerations, managing maternal and childbirth challenges, the 
identification and management of other NCDs as well as other infectious diseases.  
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HTA will also be a crucial area especially given concerns with the extent of misinformation regarding 
COVID-19 and the implications. In addition, the need for governments to prioritise their limited 
resources across disease areas (488, 489), rather than devoting appreciable personnel and 
resources to one area to the detriment of others as seen currently with activities regarding COVID-19 
(Tables 2, 2A and 3). However, there are challenges including available personnel and resources as 
well as typically a greater focus on medicines among HTA units rather than other technologies (490-
493). This is changing with studies in Ghana evaluating the cost-benefit of moderate social distancing 
policies (420) and groups in South Africa HTA evaluating the cost-effectiveness of ICU versus care on 
general wards with patients with severe COVID-19 (494).  
 
HTA and EBM will also be important in the development of clinical guidelines for Africa considering 
the costs involved with developing de-novo guidelines. Africa could certainly gain from a Pan-African 
guideline for the management of COVID-19 as knowledge grows to provide scientifically-based 
recommendations, similar to initiatives for NCDs (495). Global evidence communities including the 
BMJ under its Best Practice series are already adopting this approach for knowledge generation, 
synthesis, and translation to facilitate evidence-based decisions (75, 496), and any Pan-African 
initiatives should build on this. Groups such as IAPO are also important with their resource hubs to 
provide robust, reliable and updated information to help improve the care of patients (350). In the 
meantime, we are beginning to see African countries taking steps to reduce the level of 
misinformation and this is likely to grow (347, 348).  
 
Box 1 – National/ regional governments and authorities 
 
Leadership and governance 
• Instigation of national/ regional pandemic planning. This includes the need for active 
surveillance with appropriate personnel and facilities as well as ensuring necessary healthcare 
workforce and structures including adequate supplies of PPE and other necessary equipment, 
and communication including all key stakeholder groups with reserved funds for such health 
emergencies. In addition, a phased approach to easing restrictions when pertinent (222). Such 
activities have worked well across countries (57, 497).  
• Development and implementation of occupational health and safety protocols, policies and 
legislative frameworks taking cognisance of the risks and mechanisms of COVID-19 infection. 
Such protocols, policies and legislative frameworks should be consistent with national and 
international workplace safety policies and guidelines. Effective enforcement and monitoring 
mechanisms should be put in place 
• Planning should take account of the impact on the mental health of patients and healthcare 
professionals as well as other priority disease areas and potential ways to address these. This 
requires a sound understanding of investment/ priority decision making and activities including 
health technology assessment (HTA) evidence-based medicine (EBM) principles  
• Actively plan for misinformation building on the considerable levels of misinformation already 
seen by end June 2020 (222) 
• Good communication and financial planning are vital to address concerns with any lockdown/ 
curfew measures especially in countries with high levels of informal sector workers/ high level 
of workers dependent on a daily wage for their survival 
• Lead the development of care guidelines nationally as well as take part in the development of 
any Pan-African care guidelines. This builds on HTA/ EBM approaches 
• Ensure longer term that all healthcare professionals have the necessary training to improve the 
management of patients with infectious diseases as well as likely co-morbidities especially 
among African patients. This includes instigating antimicrobial stewardship programmes as well 
as Infection Prevention Control groups in hospitals where these do not currently exist 
• Enhance collaboration between African countries, especially those with shared borders. This 
builds on ongoing collaborations including the East African Community with their shared plans 
to tackle COVID-19 (286) 
• Explore telemedicine and other similar approaches to help with diagnosis of infectious diseases 
and address unintended consequences especially in patients with chronic NCDs (196, 207, 
421, 422) as a consequence of any lockdown, alongside investigating the potential of robots for 
care delivery 
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• Continue with measures to reduce the extent of falsified and sub-standard medicines within 
Africa as well as measures to address concerns with misinformation. Alongside this, seek ways 
to enhance local/ regional production of medicines, PPE and other equipment to reduce 
reliance on imports  
 
Health care workforce (HCW) 
• Strengthen health care systems including ambulatory care systems as well as policies and 
initiatives to improve identification and management of COVID-19, as well as other high priority 
disease areas (capacity building) 
• Instigate practices to ensure that essential health services offered by private healthcare sector 
are not compromised 
• Seek to address shortages of physicians where applicable including training and utilising of 
other healthcare professionals. This can include task shifting including a greater role for other 
professionals such as pharmacists (Box 4) As part of this, develop medium to long term 
epidemic/pandemic training for healthcare personnel to improve their preparedness and 
capacities for such health emergencies 
• Enhance the professionalism of HCWs including initiatives to reduce inappropriate prescribing 
of antimicrobials where this occurs (498) 
• Strengthen community systems through capacity building of community owned resources 
including community extension health workers as well as voluntary healthcare workers as these 
are typically the first point of contact in communities 
• Ensure HCWs continue to have access to PPE as well as additional training (where relevant) in 
dealing with pandemics as the safety of HCWs and patients is critical during pandemics 
• Seek to share basic best practices across countries, including what works well in COVID-19 
case management, infection, prevention and control.    
 
Financing/ Socioeconomic issues 
• As most African currently countries rely on foreign input, governments need to find alternative 
sources of income in the future through agriculture and technology advances building on 
current innovations 
• Minimize the socioeconomic impact through enhancing national solidarity and prioritization of 
social cohesion. 
• Seek to protect vulnerable populations including the benefits and privileges of low-wage 
workers as well as address access to healthcare and support for all to reduce the burden that 
makes vulnerable people less able to follow public health directives 
• Make it possible for small-scale business to survive periods of economic downturns occasioned 
by public health crisis. This can include facilitating the disbursement of interest loans to SMEs 
as well as reward local companies in the country with tax incentives/guaranteed bank loans to 
enable them recover post COVID-19 
 
Research including unintended consequences for both infectious diseases (including AMR) 
and non-infectious diseases 
• Promote and fund operational/national research on the impact of COVID-19 on infectious 
diseases (including AMR) and non-infectious diseases especially the unintended 
consequences (Table 3). This is particularly important in Africa where national programmes are 
just starting to address AMR as well as NCDs including CVD, diabetes and mental health (168, 
176, 178, 198, 199, 499) 
• Continue to promote research into potential risk factors for morbidity and mortality among 
African patients given the differences that can exist between patients in Africa and those in high 
income countries  
• Continue with research programmes aimed at mitigating against infectious diseases (including 
AMR) and non-infectious diseases across countries to add to the debate about the potential 
impact of unintended consequences 
• Instigate research into new ways to manage patients with both infectious diseases and NCDs 
where there are constraints on patient access including better use of new technologies 
including telemedicine and consultations through the internet/ mobile telephones 
NB: AMR = Antimicrobial Rsistance; CVD = Coronary Vascular Disease; EBM = Evidence-base medicine; HTA = 
Health Technology Assessment; NCDs = Non-communicable diseases; PPE = Personal Protective Equipment  
29 
 
 
Box 2 - Health Technology Assessment/ Evidence Based Medicine  
 
Short term 
• Continue reviewing of emerging medicines that could be used in the management of COVID-19 
to inform and update clinical protocols  
• Disseminate findings via Ministry of Health and other websites to address current levels of 
misinformation 
• Continue to undertake research for evidence-based interventions given the current 
controversies surrounding a number of suggested treatments for COVID-19, and encourage 
greater collaboration between governments, healthcare professionals and patient organisations 
researching and disseminating the findings 
• Strengthen HTA capabilities especially when Ministries of Health are confronted with different 
potential interventions to address COVID-19 coupled with limited resources. This builds on 
existing initiatives across Africa including Ghana, Kenya and South Africa as well as the recent 
cost-benefit analysis on social distancing in Ghana and ICU versus care in general wards for 
patients with severe COVID-19 (420, 493, 494, 500-502) 
• As part of this, upgrade research into priority decision making especially given the many 
competing healthcare needs among patients in Africa including those with infectious and non-
infectious diseases as well as co-morbidities 
 
Longer term 
• Seek to invest in personnel and resources to enhance HTA/ EBM capabilities within countries 
where currently limited personnel and resources to enable greater critique of evidence based 
potential alternatives  
• Seek to establish HTA collaborations across African countries to avoid duplication building on 
experiences in Europe (503-505) 
NB: EBM = Evidence-base medicine; HTA = Health Technology Assessment 
 
Box 3 – Physicians (hospital and ambulatory care) 
 
Short term 
• Deployment of higher number of physicians where possible to help deal with the pandemic as 
well as other priority disease areas. Ensure physicians are motivated emotionally, mentally and 
financially to help deal with the pandemic especially given the likely impact of the virus on their 
mental health. Educational interventions and psychological support will be needed to ensure 
greater understanding of COVID-19 and its implications including better coping strategies. 
Psychological support could include development of support systems among all stakeholders 
and general community. 
• Physicians need to be provided with adequate PPE and training to address current fears, with 
hospitals provided with adequate logistical support (PPE, ventilators, medication, non-
consumables)  
• Embrace alternative ways of working including devolved responsibilities as well as the use of 
new technologies that help improve the care of all patients during pandemics 
• Introduce greater opportunities for the training and re-training of ambulatory care physicians in 
the management of patients with COVID-19 and any co-morbidities given the challenges that 
can exist with differential diagnosis. As part of this, push for the instigation of antimicrobial 
stewardship programmes as well as IPC groups in hospitals where these do not currently exist 
• Work with others to address concerns with misinformation as well as falsified and sub-standard 
medicines. In addition, concerns with potential shortages and alternative approaches 
 
Longer term 
• Building on current experiences and collaborations on the best way to treat patients with 
COVID-19 and the aftermath including concerns with mental health disorders 
• Focus on training of sufficient physicians from non-public health or circulatory medicine 
specialities to ensure a higher number of staff with transferable skills relevant to a pandemic 
that can be rapidly re-deployed  
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• There is an urgent need generally to employ more health personnel to augment current 
inadequacies across Africa. This includes exploring measures to attain and retain physicians 
NB: PPE = Personal Protective Equipment 
 
Box 4 – Pharmacists (hospital and ambulatory care) 
 
Short term 
• Seek ways to ensure that medicines, or suitable alternatives, that are deemed helpful to 
patients with COVID-19 are routinely available coupled with medicines for other priority disease 
areas 
• Work with Government agencies when falsified or sub-standard medicines are suspected to 
reduce their supply 
• In hospitals, seek to ensure that hospital pharmacists are part of COVID-19 treatment teams 
including ASPs and IPC teams. This means that hospital pharmacist must keep abreast on 
current treatment research and protocols for COVID-19 and be familiar with EBM techniques 
given ongoing controversies (181). In addition, should be provided with any necessary PPE 
including face shields and googles 
• Hospital pharmacists should be involved in educating patients/staff on COVID-19 management 
especially on non-pharmacological and pharmacological interventions 
• Where appropriate, pharmacist should be encouraged to prepare cost-effective WHO-
recommended hand sanitizers for their facilities 
• In the community, pharmacists have a vital role as they are often the first healthcare 
professional that patients contact regarding respiratory/ influenza diseases especially in 
countries with high patient co-payments, concerns with access to ambulatory healthcare 
facilities as well as issues of affordability to pay for a physician and their medicines (168, 181, 
506-508). This includes encouraging self care/ hygiene measures including the supplying and 
wearing of masks and the need for regular hand washing as well as trying to protect patients 
against stock-outs of pertinent medicines (181, 320, 509, 510) 
• Community pharmacists can also discuss appropriate treatments including arguing against the 
need for antibiotics where this is a concern and encouraging appropriate referral where 
possible (168, 507, 509) 
• Community pharmacists and others can also push for extended supply of medicines where 
appropriate as well as help engage in discussions regarding adherence to medicines using 
different technologies especially given ongoing concerns with adherence to medicines without 
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regular input from pharmacists and other professionals (181, 511, 512). Pharmacists can also 
suggest alternative approaches during times of medicine shortages including potential OTC 
treatments (513) 
• Community pharmacists can also be involved in vaccination programmes given current 
concerns, as well as help administer a vaccine for COVID-19 when available with research 
suggesting that when pharmacists provide immunizations, they substantially increase the 
number of vaccinated people in the community (514) 
 
Longer term 
• Increase the training of Pharmacists at both hospital and community levels to be 
prepared/actively involved in management of COVID-19 patients as well as addressing 
unintended consequences including the use of technology to address issues with adherence 
• Pharmacists should be part of appropriate relevant training and the development of emergency 
plans and workflows to deal with future pandemics and their consequences (515) 
 
Box 5 – Other healthcare professionals in ambulatory and hospital care  
 
Short term 
• Work with other professionals to identify optimal methods to deal with the care of patients with 
COVID-19 both in hospitals and in the community 
• This includes making sure that healthcare professionals have the necessary PPE and 
equipment to deal with COVID-19 patients 
• Seek to instigate training regarding the proper donning and removal of PPE during routine 
duties and in the management of suspected/positive COVID-19 cases if not in place 
• Be part of ongoing plans to help improve the management of high priority disease areas 
outside of COVID-19 to make sure these patients are not neglected 
• Work with necessary professionals to ensure the mental health of healthcare professionals and 
patients is not neglected during and post the pandemic. This includes helping to address issues 
of stigma 
 
Longer term 
• Be part of elaborate plans to improve the management of patients with COVID-19 and other 
priority disease areas including re-distribution of activities to address shortages with physicians 
and other HCPs 
• Seek to work with universities, companies and other groups to develop in-house/ in-country 
technologies to treat COVID-19 patients and be less reliant on imports in the future 
 
  
32 
 
Box 6 – Suggested activities among patients/ patient organisations 
 
Short term 
• Mobilise and engage with traditional, cultural, and other leaders who are respected and listened 
to in their communities to disseminate important health messages including hygiene and social 
distance measures associated with COVID-19 to help address current low levels of health 
literacy in a number of African countries. This includes addressing current misconceptions 
about the importance of using face masks, and how to use them appropriately, as many 
patients do not appreciate their need as well as helping acknowledge that some people with 
respiratory problems may have difficulties using mask for long, which needs to be effectively 
tackled 
• Engage with various channels to help reassure COVID-19 patients that they pose no threat to 
the community after treatment, and should continue with their lives, as well as help address 
issues of stigma and discrimination against COVID-19 patients when these arise 
• Work with government bodies to help address issues of misinformation about vaccines and 
treatments including misconceptions about vaccines and the consequences (341). In addition, 
work with all key stakeholder groups to help address the mental health issues that will arise 
from the current pandemic  
• Patients organisations should work with regulatory authorities and professionals generally to 
strengthen ethical conduct and professionalism post the pandemic including promoting only 
evidence-based approaches across social and other media given concerns with the level of 
misinformation during the pandemic 
• Recovered COVID-19 patients can be used as ambassadors to sensitise the populace about 
the reality of the pandemic, and the need to avoid stigmatization 
• Social media has proved useful and can provide an efficient means for patients and patient 
organisations to communicate with their communities. However, this needs to be carefully 
managed to reduce the level of any misinformation and subsequent adverse consequences. 
This builds on activities with traditional, cultural, and other leaders 
• Empower patients on medication safety and polypharmacy concerns as well as educate 
patients about self-management generally of their conditions especially patients with chronic 
NCDs in the absence of routine clinics 
• Help explore possible telemedicine approaches to reduce reliance on clinic attendance, which 
in itself can be problematic outside of the pandemic if this involves extensive travel and waiting 
times 
 
Longer term 
• Seek to develop patient-level data bases to routinely collect data on patients to help with future 
planning and care delivery  
• Enhance the role of patient organizations within countries where pertinent as they can play a 
long-term role regarding advocacy and the spreading of information not only on COVID-19 but 
also other diseases and concerns. Patient organisations also have a key role generally to 
encourage changes in behaviours that promote good underlying health to support health 
outcomes and reduce the risk of severe symptomatic responses to a pandemic 
 
4. Discussion and next steps 
 
We believe this is the first study to comprehensively document ongoing activities throughout Africa to 
tackle the health, financial and socioeconomic consequences of COVID-19. This is important given 
the high prevalence of both infectious and non-infectious diseases in Africa, the high number of 
people at or below the poverty level compared with other continents and higher income countries, as 
well as concerns with the lack of personnel, hospital beds and equipment (168, 237-242, 255, 259, 
261). 
 
There have been different activities across Africa to prevent the spread of COVID-19 and reduce 
mortality rates (Tables 2 and 2A). African countries have broadly followed similar multiple approaches 
in terms of prevention including closing borders and instigating lockdown measures including travel 
restrictions, social distancing and testing. Closure of borders and quarantining along with other public 
health measures appear successful in reducing the spread of the virus (42), and this certainly appears 
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to be the case among a number of the African countries. Encouragingly, to date there have been no 
or very few reported deaths among some of the African countries (Tables 1 and 1A), mirroring for 
instance the situation in other LMICs including Vietnam (5). Encouragingly as well, there have been a 
number of innovations coming from the African continent to help with identification and management 
of patients with COVID-19, which includes local production of hygiene equipment as well as low-cost 
ventilators (Section 3.6). Alongside this, initiatives to enhance the production of medicines in Africa to 
reduce their reliance on imported medicines and other essential supplies. This bodes well with dealing 
with future pandemics in Africa. We will continue though to monitor prevalence and mortality rates 
across Africa as well as potential reasons for the limited mortality up to late 2020, certainly when 
compared with a number of European countries and the USA, including potential issues around 
ethnicity and other factors.  
 
However, extensive lockdown and other measures to help control the spread of the virus have been 
at a cost including the negative impact on other disease areas as well as financial and socioeconomic 
consequences (Table 3). This includes an increase in mental health disorders exacerbated by issues 
of stigma. Table 3 shows clearly the need to strengthen or enhance existing healthcare infrastructures 
in many countries to respond to such pandemics and indeed promote better population health and 
underlying lifestyle behaviours. While good health system infrastructure does not guarantee better 
health outcomes it increases the opportunities for them to happen (516).   
 
Groups such as IAPO are important to reduce any stigma associated with COVID-19 (351, 352). In 
the process of stigmatisation, people are being labelled, stereotyped, separated, and/or experience 
loss of status and discrimination because of a potential negative affiliation with the disease. Stigma 
can drive people to hide their illness to avoid discrimination, which potentially prevents them from 
promptly seeking help, and could discourage them from adopting healthy behaviours, which is 
concerning (517). This is because such barriers could potentially contribute to more severe health 
problems, ongoing transmission, and difficulties with controlling infectious diseases. As a result, there 
are ongoing strategies to address these challenges including a greater role for patient organisations 
(213).  
 
There are real concerns though if lockdown policies are eased too early due to financial and 
socioeconomic pressures (396), and we will be following this up in future research projects. We will 
also be following up the unintended consequences of COVID-19 on other infectious and non-
infectious disease areas as well as vaccination programmes. In the meantime, Boxes 1 to 6 provide 
direction to African countries going forward as they start to ease their lockdown restrictions and 
address the unintended consequences of the pandemic.  
 
Limitations 
We are aware that we have not undertaken a systematic review. This is because, as mentioned, a 
number of quoted papers have not been formally peer-reviewed and a great deal of information 
regarding country activities is currently only available on the internet. In addition, cases of COVID-19 
started later in Africa than in China and Europe, and it is too early to formally assess the impact of 
polices. A number of clinical trials regarding possible treatments for COVID-19 have also only recently 
started.  
 
However, we believe the strength of our paper lies in its comprehensive approach including ongoing 
and planned activities from across Africa and next steps from senior level personnel, which we will be 
building upon as more data becomes available. This includes activities against COVID-19 and future 
activities to re-balance the care of patients with other infectious diseases as well as NCDs. 
 
5. Conclusion 
 
There have been multiple activities across Africa to try and reduce the spread of COVID-19 with its 
subsequent impact on morbidity and mortality with the help of international and national groups 
including the WHO and African CDC. This is despite concerns with available resources, personnel 
and equipment compared with higher income countries. To date, mortality rates appear appreciably 
lower than seen in a number of European countries and the USA possibly due to early lockdown and 
other measures including early closure of borders and quarantining of returning travellers, which is 
encouraging given initial concerns in Africa. However, infection rates continue to rise which is a 
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concern especially as lockdown measures are being eased in a number of African countries. 
Encouragingly, multiple activities were typically introduced early across Africa building on the 
experiences with other infectious diseases, with countries continuing to learn from each other. 
However, there are a number of unintended consequences which are likely to result in increased 
morbidity and mortality of other infectious diseases and NCDs. Activities are ongoing to try and 
reduce the impact, and we will be monitoring these in the future.  
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